Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24736389 | 0.88 | DGAT1 (0.44) | DGAT1 | |
| SCHEMBL20531562 | 0.87 | DGAT1 (0.38) | DGAT1PDE10AKLKB1MAPT | |
| SCHEMBL19780157 | 0.87 | DGAT1 (0.38) | DGAT1PDE10AKLKB1MAPT | |
| SCHEMBL20531674 | 0.87 | DGAT1 (0.38) | DGAT1PDE10AKLKB1MAPT | |
| SCHEMBL19780512 | 0.82 | DGAT1 (0.60) | DGAT1 | |
| SCHEMBL2553654 | 0.82 | DGAT1 (0.41) | DGAT1KLKB1MAPT | |
| SCHEMBL13734459 | 0.82 | DGAT1 (0.41) | DGAT1PDE10AKLKB1MAPT | |
| SCHEMBL23620257 | 0.82 | DGAT1 (0.41) | DGAT1PDE10AKLKB1MAPT | |
| SCHEMBL13734768 | 0.81 | DGAT1 (0.40) | DGAT1PDE10AKLKB1MAPT | |
| SCHEMBL13734137 | 0.81 | DGAT1 (0.40) | DGAT1PDE10AKLKB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023250157-A9 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023250157-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-12-23 | — | — | US | disclosed |
| US-10781200-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200239435-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
| US-10301284-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-05-28 | — | — | US | disclosed |
| WO-2018011628-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-01-18 | — | — | WO | disclosed |
| EP-2699561-B1 | ANDROGEN RECEPTOR MODULATING CARBOXAMIDES | ORION CORP (FI) | 2015-06-03 | — | — | EP | disclosed |
| US-8921378-B2 | Androgen receptor modulating carboxamides | ORION CORPORATION (FI) | 2014-12-30 | — | — | US | disclosed |
| EP-2699561-A1 | ANDROGEN RECEPTOR MODULATING CARBOXAMIDES | Orion Corporation (FI) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143599-A1 | ANDROGEN RECEPTOR MODULATING CARBOXAMIDES | ORION CORPORATION (FI) | 2012-10-26 | — | — | WO | disclosed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| EP-1807407-B1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1807407-B1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1807407-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060100201-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | US | disclosed |
| WO-2006047504-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100201-A1 | Inhibitors of c-fms kinase | MUSK, FLT3, FES | DGAT1 3937/4885PDE10A 2859/4885KLKB1 2061/4885 |
| US-20200239435-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | DGAT1 2183/4885PDE10A 1883/4885KLKB1 1/4885 |
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | DGAT1 2183/4885PDE10A 1883/4885KLKB1 1/4885 |
| US-10781200-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | DGAT1 2183/4885PDE10A 1883/4885KLKB1 1/4885 |
| US-10301284-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | DGAT1 2183/4885PDE10A 1883/4885KLKB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.